Portal de Periódicos da CAPES

Pediatric lung disease: From proteinases to pulmonary fibrosis

2005; Wiley; Volume: 39; Issue: 5 Linguagem: Inglês

10.1002/ppul.20171

8755-6863

Felix Chua, Peter D. Sly, Geoffrey J. Laurent,

Peptidase Inhibition and Analysis

Pediatric PulmonologyVolume 39, Issue 5 p. 392-401 State of the Art Pediatric lung disease: From proteinases to pulmonary fibrosis Felix Chua MRCP, Corresponding Author Felix Chua MRCP [email protected] Centre for Respiratory Research, University College London, London, UKCentre for Respiratory Research, Royal Free and University College London Medical School, Rayne Institute, 5 University St., London WC1E 6JJ, UK.Search for more papers by this authorPeter D. Sly FRACP, Peter D. Sly FRACP Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia, Australia.Search for more papers by this authorGeoffrey J. Laurent PhD, Geoffrey J. Laurent PhD Centre for Respiratory Research, University College London, London, UKSearch for more papers by this author Felix Chua MRCP, Corresponding Author Felix Chua MRCP [email protected] Centre for Respiratory Research, University College London, London, UKCentre for Respiratory Research, Royal Free and University College London Medical School, Rayne Institute, 5 University St., London WC1E 6JJ, UK.Search for more papers by this authorPeter D. Sly FRACP, Peter D. Sly FRACP Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia, Australia.Search for more papers by this authorGeoffrey J. Laurent PhD, Geoffrey J. Laurent PhD Centre for Respiratory Research, University College London, London, UKSearch for more papers by this author First published: 29 March 2005 https://doi.org/10.1002/ppul.20171Citations: 9AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract One distinctive outcome of interstitial lung diseases in childhood is the abnormal accumulation of pulmonary extracellular matrix. The clinical consequence of such excessive connective tissue accumulation is known as pulmonary fibrosis. While numerous aspects of its pathogenesis have become familiar, many key events involved in its inception and progression still remain unclear. There is now compelling evidence that lung damage due to uncontrolled proteolysis may help drive critical processes that regulate fibrotic matrix remodeling. In this regard, a number of proteinases have been implicated in promoting both the initial lung injury and the fibroproliferative repair that follows. This review summarizes the knowledge of how different matrix-targeting enzymes may act to influence the development of pediatric pulmonary fibrosis. Understanding the scientific basis of this complex process may highlight opportunities to limit unwanted proteolysis and the intensity of its fibrotic sequelae. © 2005 Wiley-Liss, Inc. REFERENCES 1 Fan LL. Evaluation and therapy of chronic interstitial pneumonitis in children. Curr Opin Pediatr 1994; 6: 248–254. 2 Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial crytogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55: 143–146. 3 Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573–579. 4 Ikegamie M, Weaver TE, Conkright JJ, Sly PD, Ross GF, Whitsett JA, Glasser SW. Deficiency of SP-B reveals protective role of SP-C during oxygen lung injury. J Appl Physiol 2002; 92: 519–526. 5 Northway WH Jr, Moss RB, Carlisle KB, et al. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990; 323: 1793–1799. 6 American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304. 7 Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial pneumonitis in children. Pediatr Pulmonol 2002; 34: 23–29. 8 Stillwell PC, Norris DG, O'Connell EJ, Rosenow EC III, Weiland LH, Harrison EG Jr. Desquamative interstitial pneumonitis in children. Chest 1980; 77: 165–171. 9 Laurent GJ. Lung collagen: more then scaffolding. Thorax 1986; 41: 418–428. 10 Hacking D, Smyth R, Shaw N, Kokia G, Carty H, Heaf D. Idiopathic pulmonary fibrosis in infants: good prognosis with conservative management. Arch Dis Child 2000; 83: 152–157. 11 Chambers RC, Laurent GJ. Collagens. In: RG Crystal, J West, E Weibel, P Barnes, editors. The lung: scientific foundations, 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1997. p 709–727. 12 Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A. TIMP-1, -2, -3 and -4 in idiopathic pulmonary fibrosis: a prevailing non-degradative microenvironment? Am J Physiol Lung Cell Mol Physiol 2000; 279: 562–574. 13 Dunsmore SE, Rannels DE. Extracellular matrix biology in the lung. Am J Lung Cell Mol Physiol 1996; 270: 3–27. 14 Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–21494. 15 Infeld MD. Cell-matrix development in gland development in the lung. Exp Lung Res 1997; 23: 161–169. 16 Fukuda Y, Ishizaki M, Okada Y, Seiki M, Yamanaka N. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in fetal rabbit lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: 555–561. 17 Rolland G, Xu J, Tanswell AK, Post M. Ontogeny of extracellular matrix gene expression by rat lung cells at late fetal gestation. Biol Neonate 1998; 73: 112–120. 18 Kheradmand F, Rishi K, Werb Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP-2. J Cell Sci 2001; 115: 839–848. 19 Hayashi T, Stetler-Stevenson WG, Fleming MV, Fishback N, Koss MN, Liotta LA, Ferrans VJ, Travis WD. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol 1996; 149: 1241–1256. 20 Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis and tissue inhibitor of metalloproteinase expression. Am J Respir Cell Mol Biol 2001; 24: 591–598. 21 Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, Sheppard D, Pardo A, Selman M. Gene expression analysis revealas matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292–6297. 22 Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2000; 2: 10–19. 23 Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 2000; 275: 27123–27128. 24 Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 2000; 105: 143–150. 25 Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29: 32–36. 26 Bakowska J, Adamson IYR. Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin-induced lung injury. J Pathol 1998; 185: 319–323. 27 Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9 and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: 895–902. 28 Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol 2000; 157: 525–535. 29 Shapiro SD, Senior RM. Matrix metalloprotainses: matrix degradation and more. Am J Respir Cell Mol Biol 1999; 20: 1100–1102. 30 Van den Steen PE, Proost P, Wuyts A, van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by amino terminal processing, whereas it degrades CTAP-III, PF-4 and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96: 2673–2681. 31 Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163–176. 32 Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z. The serpin alpha-1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000; 102: 647–655. 33 Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232–237. 34 Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, Drew AF. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106: 1341–1350. 35 Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502–506. 36 Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, Laurent GJ, Chambers RC. Direct thrombin inhibition reduces lung collagen, accumulation and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159: 1383–1395. 37 Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest 1997; 99: 1313–1321. 38 Lee WL, Downey GP. State of the art. Leukocyte elastase: physiological functions and role in acute lung injury. Am J Respir Crit Care Med 2001; 164: 896–904. 39 Wolters PJ, Chapman HA. Importance of lysosomal cysteine proteases in lung disease. Respir Res 2000; 1: 170–177. 40 Ignotz RA, Massague J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261: 4337–4345. 41 Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factorβ1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768–776. 42 Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004; 113: 148–157. 43 Toti P, Buonocore G, Tanganelli P, Catella AM, Palmeri ML, Vatti R, Seemayer TA. Bronchopulmonary dysplasia of the premature baby: an immunohistochemical study. Pediatr Pulmonol 1997; 24: 22–28. 44 Lecart C, Cayabyab R, Buckley S, Morrison J, Kwong KY, Warburton D, Ramanathan R, Jones CA, Minoo P. Bioactive transforming growth factor-beta in the lungs of extremely low birthweight neonates predicts the need for home oxygen supplementation. Biol Neonate 2000; 77: 217–223. 45 Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular atrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270: 4689–4696. 46 Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 2002; 277: 21352–21360. 47 Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor-β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989; 86: 4544–4548. 48 Yehualaeshet T, O'Conner R, Begleiter A, Murphy-Ullrich JE, Silverstein R, Khalil N. A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat. Am J Respir Cell Mol Biol 2000; 23: 204–212. 49 Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor-beta 1. J Exp Med 2001; 194: 809–821. 50 Sweet DG, McMahon KJ, Curley AE, O'Connor CM, Halliday HL. Type I collagenase in bronchoalveolar lavage fluid from preterm babies at risk of developing chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2001; 84: 168–171. 51 Winkler MK, Foldes JK, Bunn RC, Fowlkes JL. Implications for matrix metalloproteinases as modulators of pediatric lung disease. Am J Physiol Lung Cell Mol Physiol 2003; 284: 557–565. 52 Dik WA, De Krijger RR, Bonekamp L, Naber BA, Zimmermann LJ, Versnel MA. Localization and potential role of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 and -2 in different phases of bronchopulmonary dysplasia. Pediatr Res 2001; 50: 761–766. 53 Pardo A, Ridge K, Uhal B, Sznajder JI, Selman M. Lung alveolar epithelial cells synthesize interstitial collagenase and gelatinises A and B in vitro. Int J Biochem Cell Biol 1997; 29: 901–910. 54 Kunugi S, Fukuda Y, Ishizaki M, Yamanaka N. Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab Invest 2001; 81: 1309–1318. 55 Vermaelen KY, Cataldo D, Tournoy K, Maes T, Dhulst A, Louis R, Foidart JM, Noel A, Pauwels R. Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a critical step in a mouse model of asthma. J Immunol 2003; 171: 1016–1022. 56 Marshall BC, Xu QP, Rao NV, Brown BR, Hoidal JR. Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha. J Biol Chem 1992; 267: 11462–11469. Citing Literature Volume39, Issue5May 2005Pages 392-401 ReferencesRelatedInformation